Skip to main content
Fig. 2 | Journal of Orthopaedic Surgery and Research

Fig. 2

From: The JNK pathway represents a novel target in the treatment of rheumatoid arthritis through the suppression of MMP-3

Fig. 2

Low-dose NAC suppressed MMP-3 expression and JNK phosphorylation. a(1) An illustrative Western blot picture of MMP-3 following low-dose NAC treatment (1000 μM) after 3 and 24 h. a(2) Normalized intensities were graphed (N = 3). Normalization was performed with MMP-3 band intensity of untreated MH7A cell (3-h incubation). b(1) An illustrative Western blot picture of phosphorylated JNK (54 and 46 kD) in MH7A cells following NAC (10, 100, and 1000 μM) for 3 and 24 h. b(2, 3) Normalized intensities were graphed (N = 3). Normalization was performed with phosphorylated JNK (p-JNK; 54 and 46 kD) of untreated MH7A cell (3-h incubation). c(1) An illustrative Western blot picture of IL-6 in MH7A cells following low-dose NAC treatment (1000 μM) after 3 or 24 h. c(2) Normalized intensities were graphed (N = 3). Normalization was performed with IL-6 bad intensity of untreated MH7A cell (3-h incubation). d This graph showed the mean concentrations of IL-6 in supernatant of MH7A cells determined by chemiluminescent enzyme immunoassay (CLEIA) following 24 h after H2O2 treatment (100 μM) and low-dose NAC treatment (1000 μM). All values are expressed as the mean ± SEM (N = 3). The significance levels are shown as *P value < .05, **P value < .01

Back to article page